m^6^A reader IGF2BP2-stabilized CASC9 accelerates glioblastoma aerobic glycolysis by enhancing HK2 mRNA stability

Hongjiang Liu1, Shan Qin2, Changqi Liu3, Le Jiang4, Chen Li1, Jiankai Yang1, Shunyao Zhang1, Zhongjie Yan1, Xiaopeng Liu1, Jipeng Yang1 and Xiaofeng Sun1,3

© The Author(s) 2021

N6-methyladenosine (m6A) has been identified to exert critical roles in human cancer; however, the regulation of m6A modification on glioblastoma multiforme (GBM) and long non-coding RNA (lncRNA) CASC9 (cancer susceptibility 9) is still unclear. Firstly, MeRIP-Seq revealed the m6A profile in the GBM. Moreover, the m6A-related lncRNA CASC9 expression was significantly elevated in the GBM tissue and its ectopic high expression was associated with poor survival, acting as an independent prognostic factor for GBM patients. Functionally, the aerobic glycolysis was promoted in the CASC9 overexpression transfection, which was inhibited in CASC9 knockdown in GBM cells. Mechanistically, m6A reader IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2) could recognize the m6A site of CASC9 and enhance its stability, then CASC9 cooperated with IGF2BP2, forming an IGF2BP2/CASC9 complex, to increase the HK2 (Hexokinase 2) mRNA stability. Our findings reveal that CASC9/IGF2BP2/HK2 axis promotes the aerobic glycolysis of GBM.

INTRODUCTION
Glioblastoma multiforme (GBM) is one of the most aggressive tumors of the central nervous system while representing 80% of all malignant brain tumors [1, 2].

Since decades GBM is characterized by a median overall survival of 15 months, suggesting the tremendous hazard of GBM [3, 4]. Although GBM is very dangerous, it is hardly excised by surgical treatment or intensive treatments, leading to a low survival rate [5]. GBM is characterized by a median overall survival around 15 months for decades, suggesting an urgent need for an accurate underlying mechanism of GBM.

N6-methyladenosine (m6A) is the most abundant modification in mRNA mediated by m6A methyltransferases, demethylases and readers [6]. m6A methyltransferases install the m6A modification on RNA, especially methyltransferase-like3 (METTL3) and its auxiliary partners METTL14 and WTAP. Currently, m6A modification is found to be involved in most pivotal biological processes, including stem cells differentiation, spermatogenesis, RNA metabolism and so on. For example, m6A demethylase ALKBH5 is highly expressed in GBM stem-like cells and ALKBH5 mediated the demethylation of FOXM1 nascent transcripts. Moreover, lncRNA FOXM1-AS accelerates the interaction of ALKBH5 and FOXM1 nascent transcripts, leading to the FOXM1 expression increasing [7]. Moreover, researchers found that the m6A level is decreased in glioma tissue and the high level of m6A results in a decreased migration and proliferation ability [8]. Therefore, these findings reveal the potential roles of m6A on GBM.

More than the DNA methylation, histone and chromatin modifications, m6A is one of the most researched hotspots in epigenetics. IGF2BP2 is one of the main RNA reader regulating human tumorigenesis. For example, upregulation of IGF2BP2 is correlated to pancreatic cancer patients' poor outcomes. Moreover, IGF2BP2 positively regulates lncRNA DANCR expression [9]. Here, our research paid close attention to the coordination within m6A and IncRNA CASC9 (cancer susceptibility 9) based on the MeRIP-Seq (methylated RNA immunoprecipitation sequencing) in GBM. CASC9 cooperated with IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2) to increase the HK2 (Hexokinase 2) mRNA stability, thereby promoting aerobic glycolysis.

RESULTS
MeRIP-Seq revealed the m6A profile in the GBM
To explore the m6A profile in the GBM, MeRIP-Seq was performed and detected. It is found that the m6A peaks frequency was mainly located in the 5-end untranslated regions (5'-UTR), coding region (CDS) and 3'-UTR (Fig. 1A). The pie chart demonstrated the distribution of m6A peaks in the GBM genome (Fig. 1B). The volcano plot displayed the upregulated or downregulated targets labeled with m6A peaks (Fig. 1C). Among the m6A motif, the GGACU motif occupied the main ingredient (Fig. 1D). Collectively, the above results implied that MeRIP-Seq revealed the m6A profile in the GBM.

m6A modified IncRNA CASC9 indicated the unfavorable prognosis of GBM
According to the data analysis of MeRIP-Seq, we found that several IncRNAs owned the m6A modified site in the RRACH motif. After
screening, several m^6^A modified lncRNAs were selected and displayed (Fig. 2A). In these candidate RNAs, we focused on the lncRNA CASC9 and investigated its functions in the GBM tumorigenesis. Firstly, in the clinically collected GBM tissue specimens, CASC9 expression elevated when compared with the adjacent normal tissue (Fig. 2B). On the basis of median value, the clinical tissue specimens were divided into high expression group and low expression group (Fig. 2C). Overall survival (OS) curve calculated by the Kaplan–Meier method for GBM patients showed that the patients who had high levels of CASC9
within tissues had remarkably shorter overall survival rate as compared to low levels of CASC9 (Fig. 2D). Clinically, CASC9 may serve as an independent factor to predict the prognosis of GBM patients. Collectively, the above results indicated that m6A modified IncRNA CASC9 indicated the unfavorable prognosis of GBM.

**m6A reader IGF2BP2 enhanced the stability of IncRNA CASC9**

In the GBM cohort, IGF2BP2 was found to be upregulated according to the GEPIA dataset (http://gepia.cancer-pku.cn/index). Western blot analysis found the IGF2BP2 expression in U87MG cells with IGF2BP2 overexpression by plasmids transfection. RNA stability assay demonstrated the remaining IncRNA CASC9 in U87MG cells when treated with Act D. MeRIP-Seq data by IGV showed the two m6A modification sites in the 3’-UTR of CASC9 (Fig. 3D). MeRIP-qPCR demonstrated that CASC9 was enriched in the GBM cell lines (U87MG) using anti-m6A antibody (Fig. 3F). Moreover, RIP (RNA-immunoprecipitation)-qPCR showed that CASC9 could interact with the IGF2BP2 in U87MG cells (Fig. 3G). In conclusion, these findings suggested that m6A reader IGF2BP2, probably via its interaction with CASC9, enhanced the stability of IncRNA CASC9, thereby promoting CASC9 expression.

LncRNA CASC9 accelerated the aerobic glycolysis of GBM

Firstly, CASC9 expression was elevated in the GBM cells (U251, U87MG) as compared to normal cells (Fig. 4A). To test whether CASC9 was essential for GBM cellular phenotype, we silenced the expression of CASC9 in GBM cells through plasmids transfection (Fig. 3B). Glucose uptake analysis, lactate production and ATP generation analysis demonstrated that CASC9 overexpression promoted the glycolytic capacity, including glucose uptake (Fig. 4C), lactate production (Fig. 4D) and ATP generation (Fig. 4E).
Meanwhile, CASC9 knockdown repressed the glycolytic capacity. In further research, extracellular acidification rate (ECAR) analysis found that CASC9 overexpression promoted the ECAR in U251 cells, and CASC9 knockdown reduced ECAR in U87MG cells (Fig. 4F). Besides, oxygen consumption rate (OCR) assay revealed that CASC9 overexpression promoted respiratory rate in U251 cells, and CASC9 knockdown reduced respiratory rate in U87MG cells (Fig. 4G). Taken together, the data suggest that CASC9 accelerated the aerobic glycolysis of GBM.

**CASC9/IGF2BP2 complex contributed to the stability of HK2 mRNA**

In the correlation analysis, we found that the expression of IGF2BP2 was positively correlated to the expression of HK2 in the
**Fig. 5** CASC9/IGF2BP2 complex contributed to the stability of HK2 mRNA. 

A. The correlation analysis within the expression of IGF2BP2 and HK2 in the GBM group, which was based on ATGC (http://gepia.cancer-pku.cn/).

B. MeRIP-Seq indicated that there was a remarkable m6A site in the 3'-UTR of HK2 mRNA.

C. The m6A site in the 3'-UTR of HK2 mRNA was AGGGACU.

D. In U251 cells, RT-PCR assay detected the HK2 mRNA levels when transfected with IGF2BP2 overexpression. In U87MG cells, RT-PCR assay detected the HK2 mRNA levels when transfected with CASC9 overexpression. E. MeRIP-qPCR assay illustrated the HK2 mRNA expression using anti-m6A antibody as compared to Input in U87MG. F. RIP-qPCR unveiled the HK2 mRNA level in U251 cells or U87MG cells using IGF2BP2 antibody. G. RNA stability assay demonstrated the HK2 mRNA in U251 cells or in U87MG cells when treated with Act D. Data are presented as the mean ± SD. **P < 0.01.
GBM group (Fig. 5A) based on the public database data (GEPIA, http://gepia.cancer-pku.cn/). According to the MeRIP-Seq, there was a remarkable m^6^A site in the 3'-UTR of HK2 mRNA (Fig. 5B). Consistent with our original hypothesis, the m^6^A site in the 3'-UTR of HK2 mRNA was identified to be AGGGACU (Fig. 5C). RT-PCR assay demonstrated that the HK2 mRNA level was increased in the IGF2BP2 overexpression transfection (U251 cells) and in the CASC9 overexpression transfection (U87MG cells) (Fig. 5D). MeRIP-PCR assay illustrated that HK2 mRNA was enriched in the anti-m^6^A antibody group as compared to the Input group (Fig. 5E). RIP-qPCR unveiled that CASC9 overexpression promoted the interaction within IGF2BP2 and HK2 mRNA, while CASC9 silencing reduced the combination within IGF2BP2 and HK2 mRNA (Fig. 5F). RNA stability assay demonstrated that CASC9 overexpression promoted the stability of HK2 mRNA in U251 cells. Moreover, IGF2BP2 overexpression could enhance the stability of HK2 mRNA in U87MG cells when treated with Act D (Fig. 5G). In conclusion, these results suggested that the function of the CASC9/IGF2BP2 complex in regulating HK2 mRNA depended on its binding to the HK2 m^6^A modification site.

DISCUSSION

Recent evidence demonstrated that m^6^A is an intense research field and exerts critical functions on human cancers, encompassing GBM [10–12]. It is known that m^6^A could regulate the metabolism of RNA, including mRNA, miRNA and IncRNAs [13, 14]. However, the potential role of m^6^A and IncRNA in GBM is still hazy.

In the data of MeRIP-Seq, we found that hundreds of potential RNA owned the m^6^A modification sites. Moreover, m^6^A peaks frequency was mainly located in the 5-end untranslated regions (5'-UTR), coding region (CDS) and 3'-UTR. Upregulated or down-regulated targets labeled with m^6^A peaks were identified. Among the m^6^A motif, the GGACU motif occupied the main ingredient. Interestingly, we found that there was an m^6^A site in the IncRNA CASC9. On account of the regulation of m^6^A on RNA metabolism, m^6^A key enzyme may function as a regulator for CASC9.

In the clinical analysis, we found that the m^6^A modified IncRNA CASC9 was upregulated in GBM and indicated the unfavorable prognosis of GBM [15]. Clinically, CASC9 may serve as an independent factor to predict the prognosis of GBM patients. In the functional assays, using CASC9 overexpression transfection and CASC9 silencing, we found that CASC9 could positively regulate the aerobic glycolysis in GBM cells. Under basal conditions, there was no difference on glucose uptake, lactate production and ECAR. Aerobic glycolysis, also known as the Warburg effect, functions as an essential initiating factor for GBM [16–18]. Aerobic glycolysis not only supports energy production but also provides the carbon skeletons for the cellular synthesis of nucleic acids in tumor cells. Besides, fatty acids act as the energetic substrates or materials for lipid membrane construction. Therefore, the energy and outcomes of aerobic glycolysis could remarkably promote the development and progression of GBM.

Another valuable finding is that the m^6^A-modified CASC9 expression was mediated by the specific m^6^A reader IGF2BP2. IGF2BP2 has been found to be upregulated in glioma and indicates a poor prognosis [19]. MeRIP-Seq displayed that there were two m^6^A modification sites in the 3'-UTR of CASC9. RNA stability assay and RT-PCR demonstrated that IGF2BP2 overexpression could enhance the stability of IncRNA CASC9 and promote its expression. Moreover, RIP illustrated that m^6^A reader IGF2BP2 significantly interacted with CASC9, highlighting a molecular interaction within IGF2BP2 and CASC9.

Given that CASC9 could regulate aerobic glycolysis, we tried to investigate the potential downstream targets of CASC9. After screening, we found that there was an obvious m^6^A site in the 3'-UTR of HK2 mRNA. Glycolytic enzyme hexokinase 2 (HK2) is a crucial regulator for the GBM Warburg effect [20, 21]. Functional analysis found that the overexpression of CASC9 could enhance the interaction within IGF2BP2 and HK2 mRNA. However, depleting CASC9 disrupted the interaction within IGF2BP2 and HK2 mRNA. RNA stability assay demonstrated that CASC9 overexpression promoted the stability of HK2 mRNA. Moreover, IGF2BP2 overexpression could enhance the stability of HK2 mRNA when treated with Act D. In public database data (GEPIA, http://gepia.cancer-pku.cn/), IGF2BP2 expression is positively correlated to HK2; however, the correlation coefficient of IGF2BP2 and HK2 is not so significant (0.2). In conclusion, these results suggested that the function of the CASC9/IGF2BP2 complex in regulating HK2 mRNA depended on its binding to the HK2 m^6^A modification site (Fig. 6).

In conclusion, we describe the function of m^6^A and IncRNA in the GBM aerobic glycolysis. CASC9/IGF2BP2 complex positively regulates the HK2 mRNA, which depended on its binding to the HK2 m^6^A modification site. Our findings uncover a critical function for m^6^A-modified IncRNA CASC9 and provide insight into a critical role of m^6^A methylation in GBM.

MATERIALS AND METHODS

Brain tissue collection

Both normal brain tissue and GBM tissue were collected during surgical specimens at The Second Hospital of Hebei Medical University (Table 1). All these processes were performed in accordance with the protocols approved by The Second Hospital of Hebei Medical University Ethics Committee in compliance with the Declaration of Helsinki. Written informed consents were obtained from all study participants before the procedure with an explanation of experimental details.

Cell culture

Normal human astrocytes (NHA) and human glioblastoma cell lines (U87MG, U21S) were purchased from the American Type Culture Collection (ATCC, USA). Cells were cultured in 1640 medium (Gibco, USA) supplemented with 10% FBS (Gibco, USA), 100 U/ml penicillin and streptomycin (Gibco, USA) in humidified 37 °C and 5% CO2 incubator (Thermo, Germany).

Table 1. Relationship between CASC9 expression and clinicopathological characteristics of GBM patients.

| Variable     | Total = 30 | CASC9 expression | p     | Gender | Total = 30 | CASC9 expression | p     |
|--------------|------------|------------------|------|--------|------------|------------------|------|
|              |            | Low = 15         |      |        |            | High = 15        |      |
| Gender       |            |                  |      |        |            |                  |      |
| Male         | 17         | 9                | 8    | 0.768  | 17         | 9                | 8    |
| Female       | 13         | 6                | 7    |        | 13         | 6                | 7    |
| Age          |            |                  |      |        |            |                  |      |
| <45          | 11         | 5                | 6    | 0.364  | 11         | 5                | 6    |
| ≥45          | 19         | 10               | 9    |        | 19         | 10               | 9    |
| Tumor size   |            |                  |      |        |            |                  |      |
| <3 cm        | 10         | 5                | 5    | 0.561  | 10         | 5                | 5    |
| 3–5 cm       | 16         | 8                | 8    |        | 16         | 8                | 8    |
| >5 cm        | 4          | 2                | 2    |        | 4          | 2                | 2    |
| WHO grading  |            |                  |      |        |            |                  |      |
| I–II         | 13         | 5                | 8    | 0.043* | 13         | 5                | 8    |
| III–IV       | 17         | 10               | 7    |        | 17         | 10               | 7    |
| KPS          |            |                  |      |        |            |                  |      |
| ≥80          | 19         | 10               | 9    | 0.427  | 19         | 10               | 9    |
| <80          | 11         | 5                | 6    |        | 11         | 5                | 6    |

KPS Karnofsky performance score, WHO World Health Organization.

*p < 0.05 represents statistical differences.
shRNA-lenti-viral construction and infection
Independent recombinant lentiviruses (pCDH-CMV-MCS-GFP) shRNA targeting CASC9 for stable knockdown were constructed by Shanghai Genechem Co., Ltd., (Shanghai, China). Stably transfected cells were chosen with 1 μg/ml puromycin (Calbiochem, USA) for 2 weeks. Overexpression CASC9 full length was synthesized and cloned into a pLKO.1-derived plasmid vector. The other siRNAs were bought by Ribobio (Gangzhou, China) and transfected into GBM cells using Lipofectamine 2000 (Invitrogen) when cells were grown to 70% confluent.

DATA AVAILABILITY
Methods details are shown in Supplementary file 1.

REFERENCES
1. Carlson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6:1359–70.
2. Liao W, Fan S, Zheng Y, Liao S, Xiong Y, Li Y. et al. Recent advances on glioblastoma multiforme and nano-drug carriers: a review. Curr Med Chem. 2019;26:3862–74.
3. Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y, Tonchev AB. Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. Med Oncol. 2018:35:27
4. Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ. et al. TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 2019:26:409–25.
5. Sasmita AO, Wong YP, Ling APK. Biomarkers and therapeutic advances in glioblastoma multiforme. Asia-Pac J Clin Oncol. 2018:14:40–51.
6. Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L. et al. Crosstalk between RNA m6A modification and non-coding RNA contributes to cancer growth and progression. Mol Ther Nucleic Acids. 2020:22:6338–44.
7. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z. et al. m6A demethylase ALKBHS maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31:391–406.e6.
8. Li F, Zhang C, Zhang G. m6A RNA methylation controls proliferation of human glioma cells by influencing cell apoptosis. Cytogenet Genome Res. 2019;159:119–25.
9. Hu X, Peng WX, Zhou H, Jiang J, Zhou X, Huang D. et al. IGF2BP2 regulates DANCIR by serving as an N6-methyladenosine reader. Cell Death Differ. 2020;27:1782–94.
10. Liu X, Qin J, Gao T, Li C, He B, Pan B. et al. YTHDF1 facilitates the progression of hepatocellular carcinoma by promoting FZD5 mRNA translation in an m6A-dependent manner. Mol Ther Nucleic Acids. 2020;22:750–65.
11. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
12. Liu ZX, Li LM, Sun HL, Liu SM. Link between m6A modification and cancers. Front Bioeng Biotechnol. 2018;6:89.
13. Yang J, Liu J, Zhao S, Tian F. N(6)-methyladenosine METTL3 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract. Mol Ther Nucleic Acids. 2020:20:111–6.
14. Zhong L, He X, Song H, Sun Y, Chen G, Si X. et al. METTL3 induces AAA development and progression by modulating N6-methyladenosine-dependent primary miRNA processing. Mol Ther Nucleic Acids. 2020:21:394–411.
15. Liu H, Li C, Yang J, Sun Y, Zhang S, Yang J. et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis. J Cell Mol Med. 2018;22:6338–44.
16. Strickland M, Stoll EA. Metabolic reprogramming in glioma. Front. Cell Dev Biol. 2017;5:43.
17. Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. Crit Rev Oncol/Hematol. 2017;132:41–58.
18. Ji J, Ding K, Luo T, Zhang X, Chen A, Zhang D. et al. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell Death Differ. 2021:28:367–81.
19. Liu X, Wu P, Su R, Xue Y, Yang C, Wang D. et al. IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay. RNA Biol. 2020:17:1777–88.
20. Sheikh T, Gupta P, Gowda P, Patrick S, Sen E. Hexokinase 2 and nuclear factor erythroid 2-related factor 2-related factor 2 transcriptionally coactivate xanthine oxidoreductase expression in stressed glioma cells. J Exp Med. 2018;293:4767–77.
21. Wolf A, Aghnhotri S, Micallef J, Mukherjee J, Sabha N, Cairns R. et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Biol Chem. 2011;286:313–26.

ACKNOWLEDGEMENTS
This work was supported by Youth Grant from the Science Foundation of Hebei Province (grant number: H2021206008), Key Research and Development Plan Program of Hebei Province (20220703D), Youth Fund for Scientific and Technological Research in Higher Education Institutions of Hebei Province (QN2018020), Key Research and Development Program of Science and Technology Department of
AUTHOR CONTRIBUTIONS
Conception and design by XS, SQ, Jiankai Y. Writing, review and revision of the manuscript by HL, C Li, C Liu, LJ. Experiments assisted by SZ, ZY, XL, Jipeng Y. The author(s) read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS STATEMENT
All experiments were approved by the Ethics Committee of The Second Hospital of Hebei Medical University.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00674-y.

Correspondence and requests for materials should be addressed to Xiaofeng Sun.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021